Ting-Chun Huang

Ting-Chun Huang

Auto-generated profile, based on publicly available information

Ting-Chun Huang

College of Medicine, National Cheng Kung University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
WCWen‐Han Cheng
Wen‐Han Cheng
LLLi-Wei Lo
Li-Wei Lo
YLYenn‐Jiang Lin
Yenn‐Jiang Lin
CLChin-Yu Lin
Chin-Yu Lin
Yu-Feng HuYu-Feng Hu
Yu-Feng Hu
SCShih-Ann Chen
Shih-Ann Chen

30 May 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
CLChih‐Min Liu
Chih‐Min Liu
LLLi-Wei Lo
Li-Wei Lo
LYLin Yenn-jiang
Lin Yenn-jiang
CLChin-Yu Lin
Chin-Yu Lin
SCShih-Lin Chang
Shih-Lin Chang
SCShih-Ann Chen
Shih-Ann Chen

21 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
PLPo‐Tseng Lee
Po‐Tseng Lee
MHMu‐Hsian Huang
Mu‐Hsian Huang
THTing‐Chung Huang
Ting‐Chung Huang
CHChi‐Hui Hsu
Chi‐Hui Hsu
SLSheng-Hsiang Lin
Sheng-Hsiang Lin
PLPing-Yen Liu
Ping-Yen Liu
Background: High burden of premature ventricular complex (PVC) leads to increased cardiovascular mortality. A recent nationwide population‐based study demonstrated that PVC is associated with an increased risk of atrial fibrillation (AF). However, the relationship between PVC burden and new‐onset AF has not been investigated. The purpose of the study is to elucidate whether PVC burden is associated with new‐onset AF. Methods and Results: We designed a single‐center, retrospective, large population‐based cohort study to evaluate the role of PVC burden and new‐onset AF in Taiwan. Patients who were AF naïve with PVC were divided into the low burden group (<1000/day) and moderate‐to‐high burden group (≥1000/day) based on the 24‐h Holter ECG report. New‐onset AF was defined as a new or first detectable event of either a persistent or paroxysmal AF. A total of 16 030 patients who were AF naïve and underwent 24‐h Holter ECG monitoring were enrolled in this study, with a mean follow‐up time of 973 days. A propensity score‐matched analysis demonstrated that the moderate‐to‐high burden PVC group had a higher risk of developing new‐onset AF than that of the low burden PVC group (4.91% versus 2.73%, P <0.001). Multivariate Cox regression analysis showed that moderate‐to‐high burden of PVC is an independent risk factor for new‐onset AF. The Kaplan–Meier analysis demonstrated that patients with moderate‐to‐high PVC burden were associated with higher risk of new‐onset AF (log‐rank P <0.001). Conclusions: PVC burden is associated with new‐onset AF. Patients with moderate‐to‐high PVC burden are at a higher risk of new‐onset AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03877614.

19 September 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
TCTing‐Yung Chang
Ting‐Yung Chang
LLLi-Wei Lo
Li-Wei Lo
ATAbigail Louise D. Te
Abigail Louise D. Te
YLYenn‐Jiang Lin
Yenn‐Jiang Lin
SCShih‐Lin Chang
Shih‐Lin Chang
SCShih‐Ann Chen
Shih‐Ann Chen

17 December 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
THTing‐Chun Huang
Ting‐Chun Huang
LYLi‐Hao Yap
Li‐Hao Yap
CCChao‐Yu Chen
Chao‐Yu Chen
HLHui Wen Lin
Hui Wen Lin
SLSheng-Hsiang Lin
Sheng-Hsiang Lin
YLYi-Heng Li
Yi-Heng Li
Background: The effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrial fibrillation (AF) has remained uncertain. This study aimed to assess whether statin use could lead to better outcomes among individuals with AF. Methods and Results: We enrolled 397 787 patients with AF from January 1, 2012 to December 31, 2020. Patients with AF were divided into 2 groups (statin user and statin nonuser), and the risks of composite outcomes (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack), all‐cause death, and major adverse cardiovascular events (which encompassed cardiovascular death, myocardial infarction, stroke, and heart failure hospitalization) were analyzed. We analyzed 288 958 patients with newly diagnosed AF (mean age, 73 years; 44% women; mean CHA 2 DS 2 ‐VASc score, 3.5). Compared with patients without statin use, statin users had lower risks of composite end points (adjusted hazard ratio [HR], 0.91 [95% CI, 0.87–0.94]; P <0.01). In regard to all‐cause death, statin users exhibited a 67% risk reduction compared with statin nonusers (adjusted HR, 0.33 [95% CI, 0.32–0.33]; P <0.01). Statin use was also associated with reduced incidence of major adverse cardiovascular events (adjusted HR, 0.64 [95% CI, 0.63–0.66]; P <0.01). In the subgroups stratified by CHA 2 DS 2 ‐VASc score, statin therapy was particularly effective for patients with CHA 2 DS 2 ‐VASc scores 0 to 3 for composite end points but consistently reduced all‐cause mortality and major adverse cardiovascular events across all score categories. Conclusions: Among patients with newly diagnosed AF, statin use was associated with lower risk of ischemic stroke, hemorrhagic stroke, transient ischemic attack, all‐cause mortality, and major adverse cardiovascular events.

1 December 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
CLChin-Yu Lin
Chin-Yu Lin
ATAbigail Louise D. Te
Abigail Louise D. Te
LYLin Yenn-jiang
Lin Yenn-jiang
SCShih-Lin Chang
Shih-Lin Chang
LLLi-Wei Lo
Li-Wei Lo
SCShih-Ann Chen
Shih-Ann Chen